Viking Therapeutics (VKTX) Accumulated Expenses (2014 - 2018)

Viking Therapeutics has reported Accumulated Expenses for 5 years, with the latest figure at $34000.0 in Q1 2018.

• Quarterly Accumulated Expenses changed N/A year-over-year to $34000.0 in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $34000.0 (changed N/A YoY) and the FY2017 annual result came in at $22000.0, down 36.95% from the prior year.
• Accumulated Expenses climbed to $34000.0 in Q1 2018 per VKTX's latest filing, from $22000.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $183611.0 in Q4 2015 and troughed at $9982.0 in Q3 2017.
• A 5-year average of $70009.8 and a median of $47113.5 in 2016 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2016 and 2017: Accumulated Expenses sank 91.37% in 2016, then soared 467.51% in 2017.
• Over 5 years, Accumulated Expenses stood at $77222.0 in 2014, then surged by 137.77% to $183611.0 in 2015, then tumbled by 81.0% to $34894.0 in 2016, then sank by 36.95% to $22000.0 in 2017, then surged by 54.55% to $34000.0 in 2018.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $34000.0, $22000.0, and $9982.0 for Q1 2018, Q4 2017, and Q3 2017 respectively.